# Savolitinib vs. Sunitinib in MET-driven PRCC.

Source: https://onco.cc/trials/nct03091192/  
OnCo record `nct03091192` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03091192
- Phase: 3
- Setting: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- Sponsor: AstraZeneca
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT03091192: https://clinicaltrials.gov/study/NCT03091192

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Savolitinib](https://onco.cc/drugs/savolitinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct03091192.json